JNJ-90858638

JNJ-90858638 is an orally bioavailable small molecule inhibitor of the interleukin-23 receptor (IL-23R), currently under development by Janssen Research & Development (a Johnson & Johnson company) for the treatment of autoimmune and inflammatory diseases. Interleukin-23 (IL-23) is a critical cytokine in the pathogenesis of several immune-mediated conditions, including psoriasis and inflammatory bowel disease, where it drives the differentiation and maintenance of Th17 cells. By specifically antagonizing the IL-23 receptor, JNJ-90858638 blocks the IL-23 signaling pathway, thereby reducing the production of downstream pro-inflammatory cytokines such as IL-17 and IL-22. As an oral small molecule, it offers a potential alternative to injectable monoclonal antibodies that target the same pathway. The compound is currently in Phase 1 clinical development, with studies evaluating its safety, pharmacokinetics, and potential drug-drug interactions in healthy participants.